TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
Clinical trial NCT02100852 · COMPLETED
Trial details
- NCT number
- NCT02100852
- Sponsor
- TG Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-03-12
- Primary completion
- 2017-11-01
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.